Abstract:The iron chelating orphan drug deferiprone (L1), discovered over 40 years ago, has been used daily by patients across the world at high doses (75-100 mg/kg) for more than 30 years with no serious toxicity. The level of safety and the simple, inexpensive synthesis are some of the many unique properties of L1, which played a major role in the contribution of the drug in the transition of thalassaemia from a fatal to a chronic disease. Other unique and valuable clinical properties of L1 in relation to pharmacology and metabolism include: oral effectiveness, which improved compliance compared to the prototype therapy with subcutaneous deferoxamine; highly effective iron removal from all iron-loaded organs, particularly the heart, which is the major target organ of iron toxicity and the cause of mortality in thalassaemic patients; an ability to achieve negative iron balance, completely remove all excess iron, and maintain normal iron stores in thalassaemic patients; rapid absorption from the stomach and rapid clearance from the body, allowing a greater frequency of repeated administration and overall increased efficacy of iron excretion, which is dependent on the dose used and also the concentration achieved at the site of drug action; and its ability to cross the blood-brain barrier and treat malignant, neurological, and microbial diseases affecting the brain. Some differential pharmacological activity by L1 among patients has been generally shown in relation to the absorption, distribution, metabolism, elimination, and toxicity (ADMET) of the drug. Unique properties exhibited by L1 in comparison to other drugs include specific protein interactions and antioxidant effects, such as iron removal from transferrin and lactoferrin; inhibition of iron and copper catalytic production of free radicals, ferroptosis, and cuproptosis; and inhibition of iron-containing proteins associated with different pathological conditions. The unique properties of L1 have attracted the interest of many investigators for drug repurposing and use in many pathological conditions, including cancer, neurodegenerative conditions, microbial conditions, renal conditions, free radical pathology, metal intoxication in relation to Fe, Cu, Al, Zn, Ga, In, U, and Pu, and other diseases. Similarly, the properties of L1 increase the prospects of its wider use in optimizing therapeutic efforts in many other fields of medicine, including synergies with other drugs.

Deferasirox (ExJade): An FDA-Approved AIEgen Platform with Unique Photophysical Properties

Deferasirox (ExJade): A Fluorescent Pro-Chelator Active Against Antibiotic Resistant Bacteria

Tuning the Solid- and Solution-State Fluorescence of the Iron-Chelator Deferasirox

In vitro studies of deferasirox derivatives as potential organelle-targeting traceable anti-cancer therapeutics

Effect of Deferasirox Combined with Erythropoietin Versus Erythropoietin Alone on Erythroid Response in Patients with Low- and Int-1-Risk Myelodysplastic Syndromes: Results of the Phase II Kallisto Trial

Deferasirox-TAT(47–57) peptide conjugate as a water soluble, bifunctional iron chelator with potential use in neuromedicine

Synthesis and Biological Evaluation of Deferiprone-Resveratrol Hybrids As Antioxidants, Aβ1–42 Aggregation Inhibitors and Metal-Chelating Agents for Alzheimer's Disease

[Deferasirox--a New Oral Iron Chelator--review].

A Small Molecular “albumin Hitchhiking” Deferoxamine Conjugate Improved Iron Clearance Efficacy

New Deferric Amine Compounds Efficiently Chelate Excess Iron to Treat Iron Overload Disorders and to Prevent Ferroptosis

A DFX-based iron nanochelator for cancer therapy

Deferasirox's Anti-Chemoresistance and Anti-Metastatic Effect on Non-Small Cell Lung Carcinoma

2D-ultrathin MXene/DOXjade platform for iron chelation chemo-photothermal therapy

Synthesis of Deferasirox,an Iron Chelator

A signal-off fluorescent strategy for deferasirox effective detection using carbon dots as probe and Cu2+ as medium

Design and Synthesis of Novel Pegylated Iron Chelators with Decreased Metabolic Rate

ATH434, a promising iron-targeting compound for treating iron regulation disorders

Deferasirox does not induce QT/QTc-prolongation in healthy subjects

The Vital Role Played by Deferiprone in the Transition of Thalassaemia from a Fatal to a Chronic Disease and Challenges in Its Repurposing for Use in Non-Iron-Loaded Diseases

Stable Luminescent Poly(Allylaminehydrochloride)-Templated Copper Nanoclusters for Selectively Turn-Off Sensing of Deferasirox in β-Thalassemia Plasma

CN128: A New Orally Active Hydroxypyridinone Iron Chelator.